RedHill Biopharma Ltd. - Form 20-F Summary (Fiscal Year Ended Dec 31, 2012)
Business Context and Reporting Period
Company: RedHill Biopharma Ltd.
Reporting Period: Fiscal year ended December 31, 2012.
Business Model: An emerging Israeli biopharmaceutical company focused on acquiring and in-licensing therapeutic candidates in advanced stages of development. The company targets improvements to existing drugs via new formulations or combinations, often utilizing the FDA's Section 505(b)(2) regulatory pathway.
Pipeline: Six late-stage clinical therapeutic candidates (RHB-101 through RHB-106) covering indications such as hypertension, nausea/vomiting, migraine, Crohn's disease, H. pylori infection, and bowel preparation. None of the candidates have received regulatory approval or generated significant commercial revenue.
Key Financial Metrics
| Metric (in thousands USD) | 2012 | 2011 |
|---|---|---|
| Revenues | $16 | $23 |
| Research & Development Expenses | $(6,455) | $(5,414) |
| General & Administrative Expenses | $(2,601) | $(2,482) |
| Operating Loss | $(9,040) | $(7,873) |
| Net Loss (Comprehensive Loss) | $(10,326) | $(15,503) |
| Cash and Short-Term Investments | $18,365 | $18,647 |
| Working Capital | $17,485 | $18,223 |
| Total Liabilities | $1,078 | $1,399 |
| Accumulated Deficit | $(23,887) | $(15,209) |
Note: The company reported no debt on its balance sheet as of December 31, 2012. Previous royalty obligations to investors were settled via share issuance in early 2013.
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by approximately $5.2 million (33%) from 2011 to 2012. This improvement was primarily driven by a significant reduction in non-cash financial expenses. In 2011, the company incurred a one-time non-cash expense of ~$7.9 million related to the revaluation of mandatory convertible loans upon conversion to equity prior to its IPO. In 2012, net financial expenses were only $1.3 million, largely due to the accretion and settlement of royalty obligations.
- Operating Expenses: Operating loss increased by $1.2 million due to a 20% rise in R&D expenses ($6.5M vs $5.4M), driven by manufacturing and clinical trial costs for RHB-102, RHB-103, RHB-104, and RHB-105. G&A expenses remained relatively flat, increasing only 4%.
- Liquidity: Cash and short-term investments remained stable at approximately $18.4 million. The company utilized $6.8 million in operating cash flows, offset by $6.6 million in financing cash flows from a private placement of shares and warrants.
Guidance, Outlook, and Risks
Outlook and Capital Needs: Management states that current cash resources ($18.4 million) are insufficient to complete the R&D for all therapeutic candidates. The company expects to incur additional losses and will require substantial additional capital through equity or debt financing, or commercialization agreements, to fund operations and clinical trials.
Key Milestones:
- RHB-103 (Migraine): Intended to file a New Drug Application (NDA) with the FDA in Q1 2013 following successful bioequivalence trials.
- RHB-102 (Nausea/Vomiting): In discussions with the FDA regarding the marketing approval pathway following positive bioavailability results.
- RHB-104 (Crohn's): Preparing Phase III trials in North America and Europe, expected to commence in Q2 2013.
Material Risks:
- Regulatory Approval: Failure to obtain FDA or foreign regulatory approval for any candidate would prevent commercialization.
- Capital Constraints: Inability to raise additional capital could force the delay or elimination of R&D programs.
- Third-Party Reliance: The company relies entirely on third parties for manufacturing and clinical trials; failures by these partners could cause delays.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political and military instability.
- PFIC Status: The company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which could have adverse tax consequences for U.S. investors.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.4 million cash balance against the projected costs of upcoming Phase III trials for RHB-104 and the NDA filing for RHB-103.
- RHB-103 NDA Filing: Confirm the submission of the NDA to the FDA in Q1 2013 as planned and monitor for any FDA responses or requests for additional data.
- Manufacturing Agreements: Review the status of the new manufacturing agreement for RHB-104 with Corealis Pharma Inc. following the termination of the previous agreement with Uman Pharma.
- Share Dilution: Monitor future capital raises, as the company explicitly states it will need to raise additional funds, likely through equity issuance which will dilute existing shareholders.
- Patent Expirations: Review the patent landscape for RHB-103 (rizatriptan) given the expiration of the Maxalt patent in late 2012 and the entry of generic competitors.